Citation Impact
Citing Papers
Global increase and geographic convergence in antibiotic consumption between 2000 and 2015
2018 Standout
Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America
2009 Standout
Activities of Micafungin against 315 Invasive Clinical Isolates of Fluconazole-Resistant Candida spp
2006
Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model
2014
Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America
2009 Standout
Environmental Study of Azole-Resistant Aspergillus fumigatus and Other Aspergilli in Austria, Denmark, and Spain
2010
Caspofungin MICs Correlate with Treatment Outcomes among Patients with Candida glabrata Invasive Candidiasis and Prior Echinocandin Exposure
2013
Frequency of Decreased Susceptibility and Resistance to Echinocandins among Fluconazole-Resistant Bloodstream Isolates of Candida glabrata
2012
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
2007 Standout
Trends in Antifungal Susceptibility among Swedish Candida Species Bloodstream Isolates from 1994 to 1998: Comparison of the E-test and the Sensititre YeastOne Colorimetric Antifungal Panel with the NCCLS M27-A Reference Method
2001
Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society
2016 Standout
Comparison of Results of Voriconazole Disk Diffusion Testing for Candida Species with Results from a Central Reference Laboratory in the ARTEMIS Global Antifungal Surveillance Program
2005
Cutting Edge: Recognition of Gram-Positive Bacterial Cell Wall Components by the Innate Immune System Occurs Via Toll-Like Receptor 2
1999 Standout
Risk factor analysis for extended-spectrum β-lactamase-producing Enterobacter cloacaebloodstream infections in central Taiwan
2013
Breakpoints for antifungal agents: An update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp.
2013
Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances
2008 Standout
Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis
2004
Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: Time for harmonization of CLSI and EUCAST broth microdilution methods
2010
Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland
2013
In Vitro Activity of β-Lactam Antimicrobial Agents in Combination with Aztreonam Tested Against Metallob-β-Lactamase-Producing Pseudomonas aeruginosa and Acinetobacter baumannii
2005
Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease
2007 Standout
Directed evolution of a para-nitrobenzyl esterase for aqueous-organic solvents
1996 StandoutNobel
Comparison of oral cefuroxime axetil and oral amoxycillin/clavulanate in the treatment of community-acquired pneumonia
1996
Oral Cefixime Is Similar to Continued Intravenous Antibiotics in the Empirical Treatment of Febrile Neutropenic Children with Cancer
2001
Evaluation of MicroScan ESBL confirmation panel for Enterobacteriaceae-producing, extended-spectrum β-lactamases isolated in Japan
2003
Staphylococcus aureus and Coagulase-Negative Staphylococci from Blood Stream Infections: Frequency of Occurrence, Antimicrobial Susceptibility, and Molecular (mecA) Characterization of Oxacillin Resistance in the SCOPE Program
1998
Guidelines for the Management of Intravascular Catheter-Related Infections
2001
Comparison of BDPhoenix and VITEK2 automated antimicrobial susceptibility test systems for extended-spectrum beta-lactamase detection in Escherichia coli and Klebsiella species clinical isolates
2003
Acquired antifungal drug resistance inAspergillus fumigatus:epidemiology and detection
2010
Evaluation of a triple-lumen central venous heparin-coated catheter versus a catheter coated with chlorhexidine and silver sulfadiazine in critically ill patients
2004
Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: A propensity-matched analysis*
2010
Severe Sepsis and Septic Shock
2013 Standout
A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: A meta-analytic/meta-regression study
2010
In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program
2004
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
2008 Standout
Antibacterial resistance worldwide: causes, challenges and responses
2004 Standout
Liposomal amphotericin B: clinical experience and perspectives
2005
Metronidazole
1997
Central Nervous System Aspergillosis
2012
A prospective survey of Aspergillus spp. in respiratory tract samples: prevalence, clinical impact and antifungal susceptibility
2011
Newer Systemic Antifungal Agents
2004
Understanding the mechanisms and drivers of antimicrobial resistance
2015 Standout
Clinical impact of rapid oxacillin susceptibility testing using a PCR assay in Staphylococcus aureus bactaeremia
1999
Antimicrobial susceptibility patterns for pathogens isolated from patients in Latin American medical centers with a diagnosis of pneumonia: analysis of results from the SENTRY Antimicrobial Surveillance Program (1997)
1998
Echinocandin antifungal drugs
2003 Standout
Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial
2014
Acne vulgaris
2011 Standout
Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria
2011
Multicenter Evaluation of the In Vitro Activity of Six Broad-Spectrum β-Lactam Antimicrobial Agents in Puerto Rico
1998
Multiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem
2002
Association of Antibiotic Utilization Measures and Control of Multiple-Drug Resistance inKlebsiella pneumoniae
2000
Reduction of Antibiotic Use in the Community Reduces the Rate of Colonization with Penicillin G--Nonsusceptible Streptococcus pneumoniae
2005
Caspofungin
2005
Hospital-Acquired Infections Due to Gram-Negative Bacteria
2010 Standout
Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations
2013
Urinary tract infections: epidemiology, mechanisms of infection and treatment options
2015 Standout
Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences
2002
Guidelines for the Prevention of Intravascular Catheter-related Infections
2011 Standout
Evolution and epidemiology of extended-spectrum β-lactamases (ESBLs) and ESBL-producing microorganisms
2001
Comparison of Mortality Associated with Methicillin‐Resistant and Methicillin‐SusceptibleStaphylococcus aureusBacteremia: A Meta‐analysis
2003 Standout
Susceptibility of clinical isolates of Candida lusitaniae to five systemic antifungal agents
2004
Evaluation of the in vitro activity of six broad-spectrum β-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan
1999
In vitro evaluation of the activity of two doses of Levofloxacin alone and in combination with other agents against Pseudomonas aeruginosa
2003
Excretion of ciprofloxacin in sweat and multiresistant Staphylococcus epidermidis
1997
Staphylococcus aureusInfections
1998 Standout
Screening and confirmatory testing for extended spectrum β-lactamases (ESBL) in Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca clinical isolates☆
2000
Nosocomial Bloodstream Infections in US Hospitals: Analysis of 24,179 Cases from a Prospective Nationwide Surveillance Study
2004 Standout
Antifungal drug resistance mechanisms in pathogenic fungi: from bench to bedside
2013
EXTENDED-SPECTRUM β-LACTAMASES AND OTHER ENZYMES PROVIDING RESISTANCE TO OXYIMINO-β-LACTAMS
1997
Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America
2019 Standout
Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management
2015 Standout
Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America
2014 Standout
Acinetobacter baumannii : Emergence of a Successful Pathogen
2008 Standout
Combination Treatment of Invasive Fungal Infections
2005
Effectiveness of Anidulafungin in Eradicating Candida Species in Invasive Candidiasis
2005
In Vitro Activities of 5-Fluorocytosine against 8,803 Clinical Isolates of Candida spp.: Global Assessment of Primary Resistance Using National Committee for Clinical Laboratory Standards Susceptibility Testing Methods
2002
In Vitro Activities of Anidulafungin against More than 2,500 Clinical Isolates of Candida spp., Including 315 Isolates Resistant to Fluconazole
2005
Detection of Extended-Spectrum β-Lactamases in Klebsiellae with the Oxoid Combination Disk Method
2000
Activities of Caspofungin, Itraconazole, Posaconazole, Ravuconazole, Voriconazole, and Amphotericin B against 448 Recent Clinical Isolates of Filamentous Fungi
2003
The emerging role of computational design in peptide macrocycle drug discovery
2020
Echinocandin and Triazole Antifungal Susceptibility Profiles for Clinical Opportunistic Yeast and Mold Isolates Collected from 2010 to 2011: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values for Characterization of Geographic and Temporal Trends of Antifungal Resistance
2013
Echinocandin Resistance in Candida Species: Mechanisms of Reduced Susceptibility and Therapeutic Approaches
2012
Detection and Reporting of Organisms Producing Extended-Spectrum β-Lactamases: Survey of Laboratories in Connecticut
1999
Coronamycins, peptide antibiotics produced by a verticillate Streptomyces sp. (MSU-2110) endophytic on Monstera sp.
2004
Carbapenemases: the Versatile β-Lactamases
2007 Standout
The carbacephems: A new beta-lactam antibiotic class
1992
Use of Epidemiological Cutoff Values To Examine 9-Year Trends in Susceptibility of Aspergillus Species to the Triazoles
2010
Occurrence and detection of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae at a veterans medical center: seek and you may find
1997
Comparison of screening methods for TEM- and SHV-derived extended-spectrum β-lactamase detection
2002
Molecular Basis of Bacterial Outer Membrane Permeability Revisited
2003 Standout
Ability of the VITEK 2 Advanced Expert System To Identify β-Lactam Phenotypes in Isolates of Enterobacteriaceae and Pseudomonas aeruginosa
2000
Cefepime: the next generation?
1993
Contemporary Tools for the Diagnosis and Management of Invasive Mycoses
2006
Evaluation of the Etest ESBL and the BD Phoenix, VITEK 1, and VITEK 2 Automated Instruments for Detection of Extended-Spectrum Beta-Lactamases in Multiresistant Escherichia coli and Klebsiella spp
2002
Caspofungin
2003
Enterobacter spp.: pathogens poised to flourish at the turn of the century
1997
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
2011 Standout
Anidulafungin and Micafungin MIC Breakpoints Are Superior to That of Caspofungin for Identifying FKS Mutant Candida glabrata Strains and Echinocandin Resistance
2013
Wild-Type MIC Distributions and Epidemiological Cutoff Values for Amphotericin B, Flucytosine, and Itraconazole and Candida spp. as Determined by CLSI Broth Microdilution
2012
AmpC β-Lactamases
2009 Standout
Bacterial Resistance to β-Lactam Antibiotics: Compelling Opportunism, Compelling Opportunity
2005 Standout
Meta-Analysis: Methods for Diagnosing Intravascular Device–Related Bloodstream Infection
2005
Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications
1997
Can Results Obtained with Commercially Available MicroScan Microdilution Panels Serve as an Indicator of β-Lactamase Production among Escherichia coli and Klebsiella Isolates with Hidden Resistance to ExpandedSpectrum Cephalosporins and Aztreonam?
1998
Influences of Methodological Variables on Susceptibility Testing of Caspofungin against Candida Species and Aspergillus fumigatus
2003
Borderline oxacillin-resistant Staphylococcus aureus (BORSA) – a more common problem than expected?
2017
Click Chemistry-Facilitated Structural Diversification of Nitrothiazoles, Nitrofurans, and Nitropyrroles Enhances Antimicrobial Activity against Giardia lamblia
2017 StandoutNobel
Extended-Spectrum β-Lactamases: a Clinical Update
2005 Standout
Invasive Candidiasis
2015 Standout
2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer
2002 Standout
Use of Microdilution Panels with and without β-Lactamase Inhibitors as a Phenotypic Test for β-Lactamase Production among Escherichia coli , Klebsiella spp., Enterobacter spp., Citrobacter freundii , and Serratia marcescens
1999
Detection of Extended-Spectrum β-Lactamases in Clinical Isolates of Enterobacter cloacae and Enterobacter aerogenes
2000
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
2016 Standout
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
2015 Standout
Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Triazoles and Six Aspergillus spp. for the CLSI Broth Microdilution Method (M38-A2 Document)
2010
Three Decades of β-Lactamase Inhibitors
2010 Standout
Computationally designed peptide macrocycle inhibitors of New Delhi metallo-β-lactamase 1
2021 StandoutNobel
Geographic Variations in Species Distribution and Echinocandin and Azole Antifungal Resistance Rates among Candida Bloodstream Infection Isolates: Report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009)
2010
Worldwide emergence of resistance to antifungal drugs challenges human health and food security
2018 StandoutScience
Variation in Susceptibility of Bloodstream Isolates of Candida glabrata to Fluconazole According to Patient Age and Geographic Location
2003
Identification of simple arylfluorosulfates as potent agents against resistant bacteria
2021 StandoutNobel
The Crisis in Antibiotic Resistance
1992 StandoutScience
Outbreak of Infection Caused by Enterobacter cloacae Producing the Novel VEB-3 Beta-Lactamase in China
2005
Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label Phase III trial
2013
Activity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies
1987
Comparison of Results of Fluconazole Disk Diffusion Testing for Candida Species with Results from a Central Reference Laboratory in the ARTEMIS Global Antifungal Surveillance Program
2004
Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Echinocandins and Candida spp
2009
Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America
2008 Standout
Methicillin-resistant staphylococci
1988
Impact of Natural Products on Developing New Anti-Cancer Agents
2009 Standout
Burn Wound Infections
2006 Standout
Comparison of Efficacy of Cefoperazone/Sulbactam and Imipenem/Cilastatin for Treatment of Acinetobacter Bacteremia
2006
EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts
2008
Triazole and Echinocandin MIC Distributions with Epidemiological Cutoff Values for Differentiation of Wild-Type Strains from Non-Wild-Type Strains of Six Uncommon Species of Candida
2011
Flucytosine Resistance Is Restricted to a Single Genetic Clade of Candida albicans
2003
Evaluation of the Etest Method Using Mueller-Hinton Agar with Glucose and Methylene Blue for Determining Amphotericin B MICs for 4,936 Clinical Isolates of Candida Species
2004
Antifungal Susceptibility Testing: Practical Aspects and Current Challenges
2001
Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat
2001 Standout
In Vitro Activities of Ravuconazole and Voriconazole Compared with Those of Four Approved Systemic Antifungal Agents against 6,970 Clinical Isolates of Candida spp
2002
Combination Therapy for Treatment of Infections with Gram-Negative Bacteria
2012
Interrogation of Related Clinical Pan-Azole-Resistant Aspergillus fumigatus Strains: G138C, Y431C, and G434C Single Nucleotide Polymorphisms incyp51A, Upregulation ofcyp51A, and Integration and Activation of TransposonAtf1in thecyp51APromoter
2011
Antimicrobial Resistance in ESKAPE Pathogens
2020 Standout
Mechanisms of Azole Resistance in Clinical Isolates of Candida glabrata Collected during a Hospital Survey of Antifungal Resistance
2005
Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship
2006 Standout
Guidelines for the Management of Intravascular Catheter-Related Infections
2001
Characterization of Clinical Isolates of Enterobacteriaceae from Italy by the BD Phoenix Extended-Spectrum β-Lactamase Detection Method
2003
The Evolving Role of Antifungal Susceptibility Testing
2013
Works of C C Knapp being referenced
Multisite reproducibility of MIC results by the Sensititre® YeaStone Colorimetric Antifungal Susceptibility Panel
1998
Timed killing kinetic studies of the interaction between ciprofloxacin and β-lactams against gram-negative bacilli
1996
Activity of cefepime, ceftazidime, and ceftizoxime against mutants of Enterobacteriaceae and Pseudomonas aeruginosa derepressed for Class I β-lactamse
1989
Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values
2012
Accuracy of Microdilution and the AutoMicrobic System in Detection of -Lactam Resistance in Gram-Negative Bacterial Mutants with Derepressed -Lactamase
1988
Comparative in vitro activity of cefoperazone and various combinations of cefoperazone/sulbactam
1990
Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria
2011
Impact of chlorhexidine-silver sulfadiazine-impregnated central venous catheters on in vitro quantitation of catheter-associated bacteria
1996
In vitro activity of metronidazole against Helicobacter pylori as determined by agar dilution and agar diffusion
1991
Multicenter Comparison of the Sensititre YeastOne Colorimetric Antifungal Panel with the NCCLS M27-A2 Reference Method for Testing New Antifungal Agents against Clinical Isolates of Candida spp
2004
Evaluation of differential inoculum disk diffusion method and Vitek GPS-SA card for detection of oxacillin-resistant staphylococci
1994
Detection of methicillin-resistant Staphylococcus epidermidis
1986
Evaluation of Vitek GPS-SA card for testing of oxacillin against borderline-susceptible staphylococci that lack mec
1996
Wild-Type MIC Distribution and Epidemiological Cutoff Values for Aspergillus fumigatus and Three Triazoles as Determined by the Clinical and Laboratory Standards Institute Broth Microdilution Methods
2009
Quality Control Limits for Broth Microdilution Susceptibility Tests of Ten Antifungal Agents
2000
Antistaphylococcal activity of a cyclic peptide, LY146032, and vancomycin
1986
Activity of new quinolones against ciprofloxacin-resistant staphylococci
1991
Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroxime
1993
Multicenter clinical laboratory evaluation of a beta-lactamase disk assay employing a novel chromogenic cephalosporin, S1
1995
Detection of extended-spectrum-beta-lactamase-producing members of the family Enterobacteriaceae with Vitek ESBL test
1996
Role of beta-lactamase and different testing conditions in oxacillin-borderline-susceptible staphylococci
1988
In vitro activities of LY163892, cefaclor, and cefuroxime
1988
Multicenter Comparison of the Sensititre YeastOne Colorimetric Antifungal Panel with the National Committee for Clinical Laboratory Standards M27-A Reference Method for Testing Clinical Isolates of Common and Emerging Candida spp., Cryptococcus spp., and Other Yeasts and Yeast-Like Organisms
1999
Evaluation of BBL crystal MRSA ID system
1994
In vitro comparison of activity of cefixime with activities of other orally administered antimicrobial agents
1988
Correlation of MIC with Outcome for Candida Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints
2008
Multicenter evaluation of the use of Haemophilus test medium for broth microdilution antimicrobial susceptibility testing of Streptococcus pneumoniae and development of quality control limits
1992